Philip Morris International Inc.
PM is executing well, but the stock already prices in a near-flawless smoke-free transition and U.S. nicotine upside at 27.51x earnings and 7.03x sales, leaving limited room for H2 investment, regulatory, and margin slippage.
PM is not expensive because the business is weak. It is expensive because the market has already given it credit for being the best-positioned large-cap tobacco name in smoke-free nicotine. That may be true strategically, but at $190.48, the stock already discounts a lot of that future. The company delivered $40.6B of FY2025 revenue, up 5.2%, but FY2025 EPS was $7.27, down 11.5%, and the shares still trade at 27.51x earnings and 7.03x sales. That is a premium not just to tobacco, but to many high-quality staples. Investors are paying for certainty that is not fully there.
The core debate is whether FY26 and FY27 earnings power can grow fast enough to justify that premium. On the positive side, PM's current guidance is solid: +5% to +7% organic revenue growth, +7% to +9% organic operating income growth, and adjusted EPS of $8.26 to $8.41. The Q2 business was good. Organic revenue grew +7.6%, smoke-free was strong, and combustibles were better than expected with +1.1% cigarette shipment growth and near-10% pricing. This is a real operating engine, not financial engineering. Management also has credibility after 8 straight quarterly EPS beats.
The problem is what changed after that strong H1. PM did not raise the full-year framework. Instead, it flagged higher than previously anticipated H2 SG&A to support ZYN and prepare IQOS ILUMA in the U.S. That may be the right long-term choice, but for a stock at this valuation, it means upside is being reinvested, not harvested. Q2 EBITDA margin was 40.5%, down 290 bps vs Q1, and management also warned about Japan category volatility in H2 around the October excise change. Those are manageable issues for the business, but they matter for a stock priced near perfection.
The SELL call depends on three things. First, valuation compresses even if fundamentals remain good. Second, incremental U.S. investment delays margin expansion. Third, the stock's setup is poor because shares sit only 8.3% below the high, so a merely good quarter may not be enough. Conviction is low because PM's moat is real and execution is strong, but avoiding overpaying for a great tobacco franchise is still the right call here.
ZYN supply and distribution expansion accelerate U.S. growth, ILUMA launch visibility improves, and investors keep paying a scarcity premium for smoke-free leadership.
PM executes on FY26 guidance but valuation normalizes as investors reassess how much of the smoke-free upside is already in the stock.
H2 U.S. investment weighs harder on margins, FDA timing slips on ILUMA, and the premium multiple compresses toward staples peers.
Quant call (SELL) diverges from analyst consensus (Strong Buy: 5 buy / 1 hold / 0 sell) — resolve explicitly.
Price is what you pay; value is what you get.
Forward earnings power is better than trailing numbers suggest, with FY26 adjusted EPS guided to $8.26 to $8.41, which puts the stock at roughly 22.6x to 23.1x forward earnings, below the trailing 27.51x but still rich for a tobacco company facing regulation and rising reinvestment needs. The moat is still real today, built on IQOS, Marlboro pricing, distribution, and now ZYN, but over 3-5 years its durability depends more on reduced-risk category leadership than on the legacy cigarette cash machine. AI is not a major direct value creator here, beyond better consumer analytics, supply planning, and trade execution, so the secular debate is mostly about nicotine product migration, FDA timing for IQOS ILUMA in the U.S., and whether oral nicotine can scale without margin dilution from sustained commercial spend. That mix supports a good business, not necessarily a good stock at $190.48.
- Valuation is stretched at 27.51x P/E versus 19.7x peer average, with a quant base value of $130.56, or -31.5% from the current $190.48.
- FY26 guidance implies continued growth, $8.26 to $8.41 adjusted EPS and +5% to +7% organic revenue growth, but PM did not raise the full-year framework after a strong H1.
- H2 margin pressure is self-inflicted, management plans stronger H2 U.S. investment behind ZYN and IQOS ILUMA prep, while Q2 EBITDA margin was 40.5%, down 290 bps vs Q1.
- Execution is consistently strong, PM beat street EPS in 8 straight quarters, including $2.20 vs $2.05 in Q2 2026 and $2.24 vs $2.09 in Q4 2025.
- Smoke-free and pricing remain powerful, Q2 organic net revenue rose +7.6%, international smoke-free H1 organic net revenue grew +13.7%, and combustible pricing was near 10% in Q2.
- FY26 guidance still calls for +7% to +9% organic operating income growth and operating cash flow around $13.5B, showing the core engine remains healthy even while funding U.S. expansion.
- Combustibles are holding up better than expected, PM improved FY cigarette volume outlook to around 2%-3% decline from 3% previously, and now expects total FY shipment volume around stable to slightly positive.
- The market is paying a premium for a consumer staples name with slowing reported earnings, FY2025 EPS fell -11.5% to $7.27 while the stock trades at 27.51x earnings and 7.03x sales.
- Management kept FY26 guidance unchanged despite stronger-than-expected H1 and Q2 delivery, suggesting upside is being absorbed by H2 spending rather than dropping through to earnings.
- Balance sheet flexibility is not pristine, total debt is $49.1B, debt/EBITDA is 2.81x, current ratio is 0.98, and financial health scores only 38/100.
- The stock setup is poor for new money, shares sit 7.6% above the 200-day average and only 8.3% below both the 52-week and 5-year high, so expectations are already elevated into the October 21, 2026 print.
| Metric | Value | Context |
|---|---|---|
| Current price | $190.48 | Reference price for the rating |
| Quant price target | $130.56 | -31.5% vs current, Low confidence, basis: earnings_growth_blend |
| FY2025 revenue | $40.6B | +5.2% YoY |
| FY2025 EPS | $7.27 | -11.5% YoY |
| Operating margin | 34.7% | down from 35.4% prior FY |
| Valuation | 27.51x P/E | 7.03x P/S | above peer averages of 19.7x and 3.2x |
| FY2026 EPS guide | $8.26 to $8.41 | includes about $0.15 currency tailwind |
| FY2026 growth guide | +5% to +7% revenue | +7% to +9% OI | organic growth targets maintained after Q2 |
| Cash generation | $13.5B OCF guide | $5.1B FCF | capex only $0.4B in the provided data |
| Leverage | 2.81x debt/EBITDA | $49.1B debt | financial health score 38/100 |
| Q2 2026 EBITDA margin | 40.5% | down 290 bps vs Q1, up 120 bps vs prior-year Q2 |
| 52-week position | -8.3% vs high | 7.6% above 200-day average | stock remains near highs into the next print |
The biggest risk to the SELL call is that PM converts its U.S. nicotine push into faster earnings power than the market expects, with FY26 adjusted EPS already guided to $8.26 to $8.41 and operating cash flow around $13.5B.
Q3 earnings on October 21, 2026, especially whether PM delivers within the $2.20 to $2.25 EPS guide while absorbing heavier H2 U.S. SG&A and whether smoke-free momentum offsets Japan volatility.
Ownership is crowded, the top 3 institutions hold 79.0%, insiders own only 0.1%, and short interest is just 0.89% of shares, down 16.7%, which argues against a squeeze-driven upside case. Options positioning is supportive near term, with a positive gamma regime and zero-gamma at $186.6, just 2.04% from spot, which can damp volatility around current levels. That setup says the shareholder base is stable, but also that there is not much bearish fuel left to unwind into a sharp rally.
Smoke-free is the growth engine, with international smoke-free H1 organic net revenue +13.7%, while combustibles still matter through near-10% Q2 pricing and +1.1% cigarette shipment growth in Q2.
ZYN is absorbing incremental H2 spend across marketing, distribution, and in-store execution, with Colorado capacity now at full-scale commercial production.
Legacy cigarettes remain a large profit pool, and FY cigarette volume outlook improved to around 2%-3% decline from 3% previously.
Japan remains important for IQOS, but management flagged further category volatility in H2 tied to the October excise change.
PM kept FY26 guidance but signaled stronger H2 U.S. investment behind ZYN and IQOS ILUMA prep.
Management has earned credibility. On the 2024 Q3 call, PM raised FY24 guidance to $6.45 to $6.51 adjusted EPS, around +9.5% organic revenue growth, and 570 million to 580 million U.S. ZYN shipments, while saying demand would be matched sometime in Q4 and 2025 capacity would reach about 900M cans. Since then, the company has posted 8 straight quarterly EPS beats, including $1.91 vs $1.82 in 2024 Q3, $2.24 vs $2.09 in 2025 Q4, and $2.20 vs $2.05 in 2026 Q2, and Colorado capacity has now reached full-scale commercial production, which supports the claim that supply expansion was real. The main miss versus the earlier optimism is not operational failure but margin timing, PM is now stepping up H2 U.S. SG&A more than previously expected and has not raised FY26 guidance despite strong H1, so execution is solid but not converting cleanly into incremental near-term earnings.
I am pleased to report a very strong Q2 as we generated +8% organic growth in net revenue and +11% in operating income, driving +14% currency-neutral progression in adjusted diluted earnings per share to $2.20 or +15% in dollar terms.
For 2026, we continue to target organic net revenue growth of +5% to +7%, organic operating income growth of +7% to +9%, and currency neutral adjusted diluted EPS growth of +7.5% to +9.5%.
In dollar terms, we now forecast a currency tailwind of around $0.15 at prevailing rates, translating into an adjusted diluted EPS range of $8.26 to $8.41, an increase of 9.5% to +11.5%.
With such an exciting lineup of new products to complement the existing portfolio, we plan to accelerate our U.S. investment in the second half.
For PMI overall, we forecast mid-single-digit Q3 organic top-line growth with modest organic margin expansion. We target adjusted diluted EPS of $2.20 to $2.25, including an unfavorable currency impact of $0.08 at prevailing exchange rates.
PM's moat comes from brand equity, global distribution, regulatory know-how, and its installed smoke-free ecosystem. Marlboro pricing still showed up at near-10% in Q2 combustibles, while IQOS and ZYN give PM a migration path that many tobacco peers do not have at global scale. The moat looks durable over the next few years, but its quality increasingly rests on reduced-risk execution and U.S. regulatory progress rather than on the old cigarette model alone.
Capital allocation is mixed. PM generated $5.1B of FCF on just $0.4B of capex, paid $2.3B in dividends, and did $0.0B of buybacks, which is sensible with debt/EBITDA at 2.81x and total debt at $49.1B. The issue is not reckless cash use, it is that a premium-valued stock is still being asked to fund heavier H2 commercial investment rather than returning more cash or delevering faster.
PM rates SELL, Low conviction. The company is executing well, the smoke-free strategy is working, and management has built credibility, but those strengths are already reflected in a stock trading at 27.51x earnings and near its highs. The base case is not business deterioration, it is valuation compression toward the engine's $130.56 target as H2 investment absorbs upside. The call would change with either a materially lower share price or evidence that ZYN and U.S. IQOS readiness are driving a step-change in earnings power beyond the current $8.26 to $8.41 FY26 guide. Until then, PM looks like a great franchise at the wrong price.
≣ Full research note tap to expand
Executive Summary
SELL, Low conviction. PM rates SELL, Low conviction. The business is strong, the earnings track record is clean, and FY26 guidance still points to growth, but the stock at $190.48 is only 8.3% below its 52-week high while the engine's base value is $130.56, or -31.5%. That gap matters more because PM trades above the 19.7x peer P/E despite only 5.2% FY2025 revenue growth and -11.5% FY2025 EPS growth, and management is now leaning into heavier H2 U.S. spending instead of flowing the upside through guidance.
Investment Thesis
PM is not expensive because the business is weak. It is expensive because the market has already given it credit for being the best-positioned large-cap tobacco name in smoke-free nicotine. That may be true strategically, but at $190.48, the stock already discounts a lot of that future. The company delivered $40.6B of FY2025 revenue, up 5.2%, but FY2025 EPS was $7.27, down 11.5%, and the shares still trade at 27.51x earnings and 7.03x sales. That is a premium not just to tobacco, but to many high-quality staples. Investors are paying for certainty that is not fully there.
The core debate is whether FY26 and FY27 earnings power can grow fast enough to justify that premium. On the positive side, PM's current guidance is solid: +5% to +7% organic revenue growth, +7% to +9% organic operating income growth, and adjusted EPS of $8.26 to $8.41. The Q2 business was good. Organic revenue grew +7.6%, smoke-free was strong, and combustibles were better than expected with +1.1% cigarette shipment growth and near-10% pricing. This is a real operating engine, not financial engineering. Management also has credibility after 8 straight quarterly EPS beats.
The problem is what changed after that strong H1. PM did not raise the full-year framework. Instead, it flagged higher than previously anticipated H2 SG&A to support ZYN and prepare IQOS ILUMA in the U.S. That may be the right long-term choice, but for a stock at this valuation, it means upside is being reinvested, not harvested. Q2 EBITDA margin was 40.5%, down 290 bps vs Q1, and management also warned about Japan category volatility in H2 around the October excise change. Those are manageable issues for the business, but they matter for a stock priced near perfection.
The SELL call depends on three things. First, valuation compresses even if fundamentals remain good. Second, incremental U.S. investment delays margin expansion. Third, the stock's setup is poor because shares sit only 8.3% below the high, so a merely good quarter may not be enough. Conviction is low because PM's moat is real and execution is strong, but avoiding overpaying for a great tobacco franchise is still the right call here.
Key Metrics
| Metric | Value | Context | |
|---|---|---|---|
| Current price | $190.48 | Reference price for the rating | |
| Quant price target | $130.56 | -31.5% vs current, Low confidence, basis: earnings_growth_blend | |
| FY2025 revenue | $40.6B | +5.2% YoY | |
| FY2025 EPS | $7.27 | -11.5% YoY | |
| Operating margin | 34.7% | down from 35.4% prior FY | |
| Valuation | 27.51x P/E | 7.03x P/S | above peer averages of 19.7x and 3.2x |
| FY2026 EPS guide | $8.26 to $8.41 | includes about $0.15 currency tailwind | |
| FY2026 growth guide | +5% to +7% revenue | +7% to +9% OI | organic growth targets maintained after Q2 |
| Cash generation | $13.5B OCF guide | $5.1B FCF | capex only $0.4B in the provided data |
| Leverage | 2.81x debt/EBITDA | $49.1B debt | financial health score 38/100 |
| Q2 2026 EBITDA margin | 40.5% | down 290 bps vs Q1, up 120 bps vs prior-year Q2 | |
| 52-week position | -8.3% vs high | 7.6% above 200-day average | stock remains near highs into the next print |
Financial Strength
PM remains financially strong enough to fund growth, but not strong enough to ignore price. Profitability and cash generation are excellent, with quality subscores of 99 for profitability and 98 for cash flow quality, and management expects about $13.5B of operating cash flow in FY26. The balance sheet is the weaker part of the story, total debt is $49.1B, leverage is 2.81x debt/EBITDA, the current ratio is 0.98, and financial health scores only 38/100. That is acceptable for a mature cash compounder, but it reduces flexibility if PM chooses to keep pressing commercial investment while maintaining dividends and defending its premium multiple.
Competitive Position
PM's moat comes from brand equity, global distribution, regulatory know-how, and its installed smoke-free ecosystem. Marlboro pricing still showed up at near-10% in Q2 combustibles, while IQOS and ZYN give PM a migration path that many tobacco peers do not have at global scale. The moat looks durable over the next few years, but its quality increasingly rests on reduced-risk execution and U.S. regulatory progress rather than on the old cigarette model alone.
Management & Guidance
Management's FY26 guide is measured and credible. PM continues to target +5% to +7% organic revenue growth, +7% to +9% organic operating income growth, and $8.26 to $8.41 adjusted EPS, while Q3 adjusted EPS is guided to $2.20 to $2.25. The guidance deserves respect because PM has beaten consensus in 8 straight quarters, but the market should also notice what management did not do: it did not raise the full-year framework after a strong H1, and explicitly warned that H2 SG&A will be higher due to stepped-up U.S. investment. That makes the guide believable, but it also caps near-term upside to earnings estimates.
Segment Analysis
- Product revenue mix (Not disclosed in the provided data): Smoke-free is the growth engine, with international smoke-free H1 organic net revenue +13.7%, while combustibles still matter through near-10% Q2 pricing and +1.1% cigarette shipment growth in Q2.
- United States oral nicotine (Not disclosed in the provided data): ZYN is absorbing incremental H2 spend across marketing, distribution, and in-store execution, with Colorado capacity now at full-scale commercial production.
- International combustibles (Not disclosed in the provided data): Legacy cigarettes remain a large profit pool, and FY cigarette volume outlook improved to around 2%-3% decline from 3% previously.
- Japan and heated tobacco markets (Not disclosed in the provided data): Japan remains important for IQOS, but management flagged further category volatility in H2 tied to the October excise change.
Capital Allocation
Capital allocation is mixed. PM generated $5.1B of FCF on just $0.4B of capex, paid $2.3B in dividends, and did $0.0B of buybacks, which is sensible with debt/EBITDA at 2.81x and total debt at $49.1B. The issue is not reckless cash use, it is that a premium-valued stock is still being asked to fund heavier H2 commercial investment rather than returning more cash or delevering faster.
Management Execution & Track Record
Management has earned credibility. On the 2024 Q3 call, PM raised FY24 guidance to $6.45 to $6.51 adjusted EPS, around +9.5% organic revenue growth, and 570 million to 580 million U.S. ZYN shipments, while saying demand would be matched sometime in Q4 and 2025 capacity would reach about 900M cans. Since then, the company has posted 8 straight quarterly EPS beats, including $1.91 vs $1.82 in 2024 Q3, $2.24 vs $2.09 in 2025 Q4, and $2.20 vs $2.05 in 2026 Q2, and Colorado capacity has now reached full-scale commercial production, which supports the claim that supply expansion was real. The main miss versus the earlier optimism is not operational failure but margin timing, PM is now stepping up H2 U.S. SG&A more than previously expected and has not raised FY26 guidance despite strong H1, so execution is solid but not converting cleanly into incremental near-term earnings.
Positioning & Flows
Ownership is crowded, the top 3 institutions hold 79.0%, insiders own only 0.1%, and short interest is just 0.89% of shares, down 16.7%, which argues against a squeeze-driven upside case. Options positioning is supportive near term, with a positive gamma regime and zero-gamma at $186.6, just 2.04% from spot, which can damp volatility around current levels. That setup says the shareholder base is stable, but also that there is not much bearish fuel left to unwind into a sharp rally.
Bull Case
- Execution is consistently strong, PM beat street EPS in 8 straight quarters, including $2.20 vs $2.05 in Q2 2026 and $2.24 vs $2.09 in Q4 2025.
- Smoke-free and pricing remain powerful, Q2 organic net revenue rose +7.6%, international smoke-free H1 organic net revenue grew +13.7%, and combustible pricing was near 10% in Q2.
- FY26 guidance still calls for +7% to +9% organic operating income growth and operating cash flow around $13.5B, showing the core engine remains healthy even while funding U.S. expansion.
- Combustibles are holding up better than expected, PM improved FY cigarette volume outlook to around 2%-3% decline from 3% previously, and now expects total FY shipment volume around stable to slightly positive.
Bear Case
- The market is paying a premium for a consumer staples name with slowing reported earnings, FY2025 EPS fell -11.5% to $7.27 while the stock trades at 27.51x earnings and 7.03x sales.
- Management kept FY26 guidance unchanged despite stronger-than-expected H1 and Q2 delivery, suggesting upside is being absorbed by H2 spending rather than dropping through to earnings.
- Balance sheet flexibility is not pristine, total debt is $49.1B, debt/EBITDA is 2.81x, current ratio is 0.98, and financial health scores only 38/100.
- The stock setup is poor for new money, shares sit 7.6% above the 200-day average and only 8.3% below both the 52-week and 5-year high, so expectations are already elevated into the October 21, 2026 print.
Valuation & Price Target
Engine price target $130.56 (-31.5% vs current), Low confidence.
- P/E Multiple: $141.28 (28% weight)
- PEG (growth-adjusted): $54.29 (20% weight)
- P/S Multiple: $83.01 (20% weight)
- Quality-adjusted: $220.96 (20% weight)
- DCF: $163.74 (11% weight)
The quant baseline says SELL (Low conviction) and that call is reasonable to keep. The business quality score is high at 70/100, profitability is 99, cash flow quality is 98, and FY26 adjusted EPS guidance of $8.26 to $8.41 means PM is still growing, so this is not a broken-company short. The issue is price: 27.51x P/E versus 19.7x peers, 7.03x P/S versus 3.2x peers, and a quant target of $130.56 built from a blend where even the more forgiving methods cluster below the current price, except the quality-adjusted view at $220.96. Given the wide peer P/E dispersion of 3.9x and PM's superior smoke-free assets, conviction stays low, but the current stock price still looks too high relative to the guided growth and H2 spending profile. Sell-side consensus is Strong Buy, but with only 6 firms and low signal value, it is not persuasive against the valuation gap.
Risk Assessment
Risk score 43/100 (Moderate). The biggest risk to the SELL call is that PM converts its U.S. nicotine push into faster earnings power than the market expects, with FY26 adjusted EPS already guided to $8.26 to $8.41 and operating cash flow around $13.5B.
The Bottom Line
PM rates SELL, Low conviction. The company is executing well, the smoke-free strategy is working, and management has built credibility, but those strengths are already reflected in a stock trading at 27.51x earnings and near its highs. The base case is not business deterioration, it is valuation compression toward the engine's $130.56 target as H2 investment absorbs upside. The call would change with either a materially lower share price or evidence that ZYN and U.S. IQOS readiness are driving a step-change in earnings power beyond the current $8.26 to $8.41 FY26 guide. Until then, PM looks like a great franchise at the wrong price.
Go deeper in the app
Live charts, options analytics, the full earnings-call breakdown, price alerts, and every other stock — updated in real time.
Get Tickr